AYTU
Aytu BioPharma, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$2.21
−3.28%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 56.6M | 66.4M | 65.2M | 107.4M | 96.7M |
| Cost of Revenue | 21.2M | 20.6M | 16.1M | 40.8M | 46.4M |
| Gross Profit | 35.4M | 45.8M | 49.1M | 66.6M | 50.3M |
| Operating Expenses | |||||
| R&D Expense | 216.0K | 1.3M | 2.8M | 4.1M | 12.7M |
| SG&A Expense | 40.7M | 38.3M | 42.0M | 70.1M | 69.9M |
| General & Admin Expense | 18.7M | 17.4M | 20.0M | 28.6M | 31.2M |
| Selling & Marketing Expense | 22.0M | 20.9M | 22.1M | 41.4M | 38.7M |
| Other Expenses | 9.6M | 14.0M | 5.8M | 9.5M | 77.6M |
| Total Operating Expenses | 50.5M | 53.7M | 50.6M | 83.7M | 160.2M |
| Cost and Expenses | 71.8M | 74.2M | 66.8M | 124.5M | 206.6M |
| Operating Income (EBIT) | (15.2M) | (7.8M) | (1.6M) | (17.1M) | (109.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 14.0K |
| Interest Expense | 2.2M | 3.7M | 4.8M | 5.0M | 147.5M |
| Net Interest Income | (2.2M) | (3.7M) | (4.8M) | (5.0M) | (147.5M) |
| Other Non-Op Income/Expense | (18.5M) | (5.9M) | (8.8M) | 14.0K | 1.0M |
| Non-Operating Income (excl Interest) | 16.3M | 2.2M | 3.7M | (5.0M) | (71.8M) |
| EBT (Pre-Tax Income) | (33.7M) | (13.7M) | (10.4M) | (17.1M) | (108.9M) |
| Income Tax Expense | 447.0K | 437.0K | 2.1M | — | (110.0K) |
| Bottom Line | |||||
| Net Income | (34.1M) | (13.6M) | (15.8M) | (17.1M) | (108.8M) |
| Earnings from Cont. Ops | (34.1M) | (14.2M) | (12.5M) | (17.1M) | (108.8M) |
| Earnings from Discont. Ops | 62.0K | 620.0K | (3.3M) | — | — |
| Bottom Line Net Income | (37.5M) | (13.6M) | (15.8M) | (17.1M) | (108.8M) |
| Per Share | |||||
| Basic EPS | ($4.29) | ($2.16) | ($2.86) | ($5.11) | ($74.01) |
| Diluted EPS | ($4.58) | ($2.16) | ($2.86) | ($5.11) | ($74.01) |
| Revenue Per Share | $5.38 | $10.57 | $11.77 | $32.16 | $65.76 |
| Shares | |||||
| Basic Shares Outstanding | 10.5M | 6.3M | 5.5M | 3.3M | 1.5M |
| Diluted Shares Outstanding | 10.5M | 6.3M | 5.5M | 3.3M | 1.5M |
| Profitability Metrics | |||||
| EBITDA | (27.3M) | (4.7M) | 1.4M | (3.3M) | (28.0M) |
| D&A | 4.1M | 5.4M | 6.7M | 8.8M | 10.1M |
| EBIT | (31.4M) | (10.0M) | (5.3M) | (12.1M) | (38.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026